Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity
Phytomedicine · 2023
DOI: 10.1016/j.phymed.2023.154990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2023. Verfasst von Qingqing Ruan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a malignant pancreatic tumor charactered by a rapid progression and high lethal rate. Hyperactivation of STAT3 signaling exerts a vital effect on the growth and progression of PDAC. While dietary flavonoid phloretin has anti-inflammatory and antioxidant activities, it remains unclear whether phloretin has anti-tumor effects on PDAC. PURPOSE: The focus of the present study is to elucidate the effects of phloretin on PDAC and investigate its underlying molecular mechanisms. STUDY DESIGN AND METHODS: Effect of phloretin were assessed in the pancreatic cancer cells (PCCs) by colony formation assay, real-time cell analysis, flow cytometry, Immunofluorescence staining, and cell migration assay. The expressions of mRNA and protein were respectively analyzed by quantitative PCR and Western blotting. A xenograft model was used to appraise the antitumor efficacy of phloretin. RESULTS: Phloretin treatment significantly restrained cell viability and metastasis, induced DNA injury and ROS accumulation, and triggered mitochondrial-dependent apoptosis in PCCs. Mechanistically, phloretin exhibits anti-tumor potential via inactivating STAT3 signaling and enhancing Nrf2 activity. STAT3 overexpression and Nrf2 silencing partially relieved phloretin-induced inhibition on cell growth and metastasis in PCCs. Phloretin remarkably blocked pancreatic tumor growth and metastasis in vivo. CONCLUSIONS: Phloretin suppresses pancreatic cancer growth and progression through inhibition of STAT3 mediated by enhancing Nrf2 activity. Phloretin may serve as a promising therapeutic agent for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China; National Key Clinical Specialty (G…
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
- Department of Public Health, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang People's Hospital, Jinhua 321000, China.
Zitieren
APA
Ruan, Q., Wen, C., Jin, G., Yuan, Z., Yang, X., Wen, Z., Huang, G., Li, G., Deng, J., & Bai, Y. (2023). Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity. Phytomedicine. https://doi.org/10.1016/j.phymed.2023.154990
Vancouver
Ruan Q, Wen C, Jin G, Yuan Z, Yang X, Wen Z, et al. Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity. Phytomedicine. 2023. doi:10.1016/j.phymed.2023.154990
BibTeX
@article{Ruan2023,
author = {Ruan, Qingqing and Wen, Chunmei and Jin, Guihua and Yuan, Ziwei and Yang, Xuejia and Wen, Zhikai and Huang, Gang and Li, Guogang and Deng, Jie and Bai, Yongheng},
title = {Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity},
journal = {Phytomedicine},
year = {2023},
doi = {10.1016/j.phymed.2023.154990}
}
EUVIMED